ThisiscontentfromElsevier'sDrugInformation

    Rucaparib

    Learn more about Elsevier's Drug Information today! Get the drug data and decision support you need, including TRUE Daily Updates™ including every day including weekends and holidays.

    Mar.28.2024

    Rucaparib

    Indications/Dosage

    Labeled

    • ovarian cancer
    • prostate cancer

    Off-Label

      † Off-label indication

      For the treatment of ovarian cancer

      NOTE: Rucaparib is designated by the FDA as an orphan drug for this indication.

      for the maintenance treatment of BRCA-mutated (germline and/or somatic) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after a complete or partial response to platinum-based chemotherapy, as monotherapy

      Oral dosage

      Adults

      600 mg orally twice daily until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. The investigator-assessed median progression-free survival time was significantly improved in patients with BRCA-mutated, platinum-sensitive, recurrent ovarian, primary peritoneal, or fallopian tube carcinoma who received rucaparib compared with placebo (16.6 months vs. 5.4 months; hazard ratio (HR) = 0.23; 95% CI, 0.16 to 0.34) in a subgroup analysis (n = 196) of a randomized (2:1), phase 3 (ARIEL3) trial. At the final overall survival (OS) analysis, the median OS times were 45.9 months and 47.8 months (HR = 0.83; 95% CI: 0.58 to 1.19) in patients with a BRCA-mutation who received rucaparib and placebo, respectively. The median age was 58 (range, 42 to 81) years in patients with a BRCA-mutation who received rucaparib; in these patients, all had received at least 2 (range, 2 to 5) previous platinum-based chemotherapy regimens and 22% of patients had received prior bevacizumab therapy.[61608]

      for the treatment of BRCA mutation-positive (germline and/or somatic) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received 2 or more prior chemotherapy regimens, as monotherapy†

      Oral dosage

      Adults

      Dosage not available.

      For the treatment of prostate cancer

      for the treatment of BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (CRPC) in patients who have previously been treated with androgen receptor-directed therapy and a taxane-based chemotherapy

      Oral dosage

      Adults

      600 mg PO twice daily until disease progression or unacceptable toxicity. Patients should concurrently receive treatment with a gonadotropin-releasing hormone (GnRH) analog or have had a bilateral orchiectomy. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Treatment with rucaparib resulted in a confirmed objective response rate of 44% in patients with BRCA-mutated metastatic CRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy in an ongoing multicenter, noncomparative trial. The median duration of response was not evaluable.[61608]

      Therapeutic Drug Monitoring

      Dosage Adjustments for Treatment-Related Toxicities:

      • First Dose Reduction: 500 mg orally twice daily
      • Second Dose Reduction: 400 mg orally twice daily
      • Third Dose Reduction: 300 mg orally twice daily

      Hematologic Toxicity

      • Grade 1 or higher hematologic toxicity: Hold rucaparib therapy and monitor CBC weekly. When toxicity resolves to grade 1 or less, rucaparib therapy may be resumed; if resolution has not occurred by 4 weeks, refer the patient to a hematologist for further evaluation.[61608]

      Maximum Dosage Limits

      • Adults

        600 mg PO twice daily.[61608]

      • Geriatric

        600 mg PO twice daily.[61608]

      Patients with Hepatic Impairment Dosing

      Baseline Hepatic Impairment:

      • Mild to moderate hepatic impairment (total bilirubin less than or equal to 3 times the upper limit of normal [ULN] and AST greater than ULN): No dosage adjustment necessary.
      • Severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST): Rucaparib has not been studied in this population.[61608]

      Patients with Renal Impairment Dosing

      Baseline Renal Impairment:

      • Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No dosage adjustment necessary.
      • Severe renal impairment (CrCl less than 30 mL/min) or hemodialysis: Rucaparib has not been studied in this population.[61608]
      † Off-label indication
      Revision Date: 03/28/2024, 01:48:00 AM

      References

      61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.67677 - Clovis Oncology, Inc. Important Prescribing Information, May 2022. Subject: Final Data from Study CO-338-043 (ARIEL4) Show a Decrease in Overall Survival for Rubraca® (Rucaparib) Compared to Standard of Care. Retrieved June 14, 2022. Available on the World Wide Web at: https://clovisoncology.com/pdfs/US_DHCPL_final_signed.pdf.

      How Supplied

      Rucaparib Oral tablet

      Rubraca 200mg Tablet (69660-0201) (Clovis Oncology, Inc.) null

      Rucaparib Oral tablet

      Rubraca 250mg Tablet (69660-0202) (Clovis Oncology, Inc.) null

      Rucaparib Oral tablet

      Rubraca 300mg Tablet (69660-0203) (Clovis Oncology, Inc.) null

      Description/Classification

      Description

      Rucaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. It is indicated for the maintenance treatment of BRCA-mutated recurrent ovarian cancer after a response to platinum-based chemotherapy and for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer in patients previously treated with androgen receptor-directed therapy and taxane-based chemotherapy. PARP enzymes are involved in normal cellular homeostasis, including DNA transcription, cell cycle regulation, and DNA repair; increased cytotoxicity and anti-tumor activity has been noted in cell lines and mouse tumor models with deficiencies in BRCA. The most common grade 3 or 4 adverse reactions occurring in more than 10% of patients included anemia, asthenia/fatigue, increased ALT, and neutropenia.[61608]

      Classifications

      • Antineoplastic and Immunomodulating Agents
        • Antineoplastics
          • Small Molecule Antineoplastic Poly (ADP-ribose) Polymerase (PARP) Inhibitors
      Revision Date: 03/28/2024, 01:48:00 AM

      References

      61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

      Administration Information

      General Administration Information

      For storage information, see the specific product information within the How Supplied section.

      Emetic Risk

      • Moderate/High
      • Administer routine antiemetic prophylaxis prior to treatment.[67389]

      Route-Specific Administration

      Oral Administration

      • Take tablets with or without food. Administration with a high-fat meal increases the Cmax and AUC of rucaparib (by 20% and 38%, respectively), and delays clearance by 2.5 hours.
      • If a dose is missed, the patient should take the next dose at the regularly scheduled time; do not replace doses if vomiting occurs.[61608]

      Clinical Pharmaceutics Information

      From Trissel's 2‚Ñ¢ Clinical Pharmaceutics Database
        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.67389 - Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020 Aug 20;38(24):2782-2797.

        Adverse Reactions

        Mild

        • abdominal pain
        • anorexia
        • asthenia
        • diarrhea
        • dizziness
        • dysgeusia
        • dyspepsia
        • fatigue
        • fever
        • flushing
        • headache
        • infection
        • insomnia
        • maculopapular rash
        • nausea
        • pharyngitis
        • photosensitivity
        • pruritus
        • rash
        • urticaria
        • vomiting

        Moderate

        • anemia
        • bleeding
        • constipation
        • depression
        • dyspnea
        • edema
        • elevated hepatic enzymes
        • hypercholesterolemia
        • hypertriglyceridemia
        • hyponatremia
        • hypophosphatemia
        • leukopenia
        • lymphopenia
        • neutropenia
        • palmar-plantar erythrodysesthesia (hand and foot syndrome)
        • peripheral edema
        • psoriasis
        • stomatitis
        • thrombocytopenia
        • wheezing

        Severe

        • abdominal pain
        • anemia
        • anorexia
        • asthenia
        • constipation
        • diarrhea
        • elevated hepatic enzymes
        • exfoliative dermatitis
        • fatigue
        • hypercholesterolemia
        • hypertriglyceridemia
        • leukopenia
        • lymphopenia
        • nausea
        • neutropenia
        • new primary malignancy
        • rash
        • renal failure (unspecified)
        • stomatitis
        • thrombocytopenia
        • thromboembolism
        • vomiting

        New primary malignancy, including acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), occurred in 32 of 1,594 patients (2%) with ovarian cancer treated with rucaparib, after a duration of therapy ranging from less than 2 months to about 72 months. These cases were typical of cancer therapy-related MDS/AML; all patients had received prior treatment with platinum-containing chemotherapy and other DNA damaging agents. Fourteen cases (0.9%) occurred during treatment or during the 28-day safety follow-up. MDS/AML was not observed in patients with metastatic castration-resistant prostate cancer (n = 209), regardless of homologous recombination deficiency (HRD) mutation. Monitor complete blood counts (CBC) prior to starting therapy and monthly thereafter. Rucaparib should not be started until any prior hematologic toxicity resolves to grade 1 or lower. If recovery to grade 1 or less has not occurred within 4 weeks, the patient should be referred to a hematologist for further investigations including a bone marrow analysis and cytogenetics. Rucaparib should be discontinued if a diagnosis of MDS or AML is confirmed.[61608]

        Neutropenia occurred in 22% of patients who received rucaparib maintenance therapy for platinum-sensitive BRCA-mutated recurrent ovarian cancer compared with 6% of those who received placebo (grade 3 or 4, 8% vs. 0%). A decrease from baseline in leukocytes (leukopenia) (39% to 69%; grade 3 or 4, 3% to 5%), neutrophils (neutropenia) (38% to 62%; grade 3 or 4, 6% to 10%), and lymphocytes (lymphopenia) (33% to 42%; grade 3 or 4, 7% to 17%) were also reported in these patients and in patients with BRCA-mutated metastatic, castration-resistant prostate cancer in a nonrandomized trial.[61608]

        Constipation occurred in 27% to 39% (grade 3 or 4, 1% to 4%) and diarrhea in 20% to 34% (grade 3 or 4, 2% or less) of patients treated with rucaparib in clinical trials.[61608]

        Fatigue/asthenia occurred in 74% of patients receiving rucaparib maintenance therapy for platinum-sensitive BRCA-mutated recurrent ovarian cancer compared with 52% of those who received placebo (grade 3 or 4, 9% vs. 5%) in a randomized clinical trial and was among the most common adverse reactions leading to dose reductions. Fatigue/asthenia was also reported in 62% (grade 3 or 4, 9%) of patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a noncomparative trial.[61608]

        Mild dysgeusia (33% vs. 6%) occurred more often in patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated recurrent ovarian cancer compared with placebo in a randomized, double-blind clinical trial. The incidence of dysgeusia was lower in a noncomparative trial of patients with BRCA-mutated, metastatic castration-resistant prostate cancer (less than 20%).[61608]

        Anorexia occurred more often in patients receiving maintenance therapy with rucaparib for BRCA-mutated, recurrent, platinum-sensitive ovarian cancer compared with placebo in a randomized, double-blind clinical trial (23% vs. 14%; grade 3 or 4, 2% vs. 0%). It was also reported in 28% (grade 3 or 4, 2%) of rucaparib-treated patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a nonrandomized trial.[61608]

        Dyspnea occurred in 17% of patients receiving rucaparib as maintenance therapy for BRCA-mutated ovarian cancer in a randomized clinical trial; it was also reported in less than 20% of patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a noncomparative trial.[61608]

        Rash occurred in 45% of patients receiving rucaparib maintenance therapy for platinum-sensitive BRCA-mutated ovarian cancer compared with 23% of those who received placebo in a randomized, double-blind clinical trial. Rash also occurred in 27% (grade 3 or 4, 2%) of patients with BRCA-mutated, metastatic castration-resistant prostate cancer, including blisters, blood blisters, contact dermatitis, eczema, genital rash, palmar-plantar erythrodysesthesia (hand and foot syndrome), photosensitivity, pruritus, psoriasis, maculopapular rash, exfoliative dermatitis, and urticaria.[61608]

        Naso-pharyngitis/upper respiratory tract infection occurred more often in patients receiving maintenance therapy with rucaparib for platinum-sensitive, BRCA-mutated recurrent ovarian cancer compared with placebo in a randomized, double-blind clinical trial (29% vs. 20%; grade 3 or 4, 0% vs. 2%); fever was reported in 15% of patients. Urinary tract infection, pneumonia, and sepsis were each reported in less than 20% of rucaparib-treated patients with BRCA-mutated metastatic castration-resistant prostate cancer in a noncomparative trial. Pneumonia, sepsis, and urinary tract infection were reported in less than 20% of patients.[61608]

        Elevated hepatic enzymes have been reported in patients treated with rucaparib in clinical trials. Increased AST/ALT levels were reported in 33% of patients receiving rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated ovarian cancer in a randomized, double-blind clinical trial compared with 3% of those who received placebo (grade 3 or 4, 16% vs. 0%); increased ALT/AST levels were reported in 33% of rucaparib-treated patients with BRCA-mutated metastatic prostate cancer (grade 3 or 4, 5%). Compared to baseline, an increase in AST/ALT levels occurred in 59% to 69% (grade 3 or 4, 1% to 11%) and an increase in alkaline phosphatase level occurred in 39% to 44% (grade 3 or 4, 2% or less) of patients in these trials.[61608]

        An increase in cholesterol level (hypercholesterolemia) from baseline occurred in 39% (grade 3 or 4, 3%) of patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated recurrent ovarian cancer in a randomized, double-blind clinical trial compared with 20% of those who received placebo. An increase in triglycerides from baseline (e.g., hypertriglyceridemia) was reported in 42% of rucaparib-treated patients with BRCA-mutated prostate cancer in a noncomparative trial.[61608]

        An increase in serum creatinine level from baseline occurred in 96% of patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated recurrent ovarian cancer receiving in a randomized, double-blind clinical trial compared with 89% of those who received placebo; in rare cases, renal failure (unspecified) occurred. Renal failure was reported in less than 20% of rucaparib-treated patients with BRCA-mutated, metastatic prostate cancer, while an increase in creatinine occurred in 43% of these patients (grade 3 or 4, 2%).[61608]

        A hypersensitivity reaction including flushing, asthma, chocking sensation, eyelid edema, facial edema, and wheezing, was reported in less than 20% of rucaparib-treated patients with BRCA-mutated, metastatic castration-resistant prostate cancer.[61608]

        Headache occurred in 22% and dizziness in 15% of patients receiving rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated ovarian cancer in a randomized, double-blind clinical trial. Dizziness was also reported in less than 20% of patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a separate noncomparative trial.[61608]

        Nausea was reported in 79% (grade 3 or 4, 2%) of patients receiving rucaparib as maintenance therapy for BRCA-mutated ovarian cancer in a randomized clinical trial; vomiting occurred in 37% (grade 3 or 4, 4%) of these patients. The incidence of nausea (52%; grade 3 or 4, 3%) and vomiting (22%; grade 3 or 4, 1%) was slightly lower in rucaparib-treated patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a noncomparative trial.[61608]

        Abdominal pain/distention was less common in patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated recurrent ovarian cancer compared with placebo in a randomized, double-blind clinical trial (48% vs. 49%; grade 3 or 4, 3% vs. 2%).[61608]

        Stomatitis occurred more often in patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated recurrent ovarian cancer compared with placebo in a randomized, double-blind clinical trial (28% vs. 12%; grade 3 or 4, 0.8% vs. 0%). Stomatitis was reported in less than 20% of rucaparib-treated patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a noncomparative trial.[61608]

        Dyspepsia was reported in 12% of patients receiving maintenance therapy with rucaparib after a response to platinum-containing chemotherapy for BRCA-mutated, recurrent ovarian cancer in a randomized, double-blind clinical trial. It was also reported in less than 20% of patients with BRCA-mutated, metastatic castration-resistant prostate cancer treated with rucaparib in a noncomparative trial.[61608]

        Anemia occurred in 41% of patients who received rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated recurrent ovarian cancer compared with 6% of those who received placebo (grade 3 or 4, 26% vs. 0%); it was also reported in 43% (grade 3 or 4, 25%) of patients with BRCA-mutated metastatic, castration-resistant prostate cancer in a nonrandomized trial. Additionally, a decrease in hemoglobin level from baseline was reported in 59% to 61% (grade 3 or 4, 18% to 25%) of those who received rucaparib.[61608]

        Thrombocytopenia occurred in 35% of patients who received rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated recurrent ovarian cancer compared with 3% of those who received placebo (grade 3 or 4, 6% vs. 0%); it was also reported in 25% (grade 3 or 4, 10%) of patients with BRCA-mutated metastatic, castration-resistant prostate cancer in a nonrandomized trial. Additionally, a decrease in platelets from baseline was reported in 40% to 47% (grade 3 or 4, 2% to 10%) of those who received rucaparib.[61608]

        Bleeding was reported in less than 20% of rucaparib-treated patients with BRCA-mutated, metastatic castration-resistant prostate cancer in a noncomparative trial.[61608]

        A decrease in serum phosphate levels from baseline (hypophosphatemia) occurred in 68% of rucaparib-treated patients with BRCA-mutated metastatic prostate cancer in a nonrandomized trial (grade 3 or 4, 15%); a decrease in sodium from baseline (hyponatremia) was reported in 38% of these patients (grade 3 or 4, 3%).[61608]

        Venous thromboembolism and ischemic cardiovascular events were each reported in less than 20% of patients with BRCA-mutated, metastatic castration-resistant prostate cancer treated with rucaparib in a nonrandomized trial.[61608]

        Insomnia (19%) and depression (11%) were reported in patients who received rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated recurrent ovarian cancer in a randomized clinical trial.[61608]

        Peripheral edema was reported in 12% of patients who received rucaparib maintenance therapy for platinum-sensitive, BRCA-mutated recurrent ovarian cancer in a randomized clinical trial.[61608]

        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

        Contraindications/Precautions

        Absolute contraindications are italicized.

        • breast-feeding
        • contraception requirements
        • leukemia
        • male-mediated teratogenicity
        • myelodysplastic syndrome (MDS)
        • pregnancy
        • pregnancy testing
        • reproductive risk

        Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) has been reported in 20 patients who received rucaparib therapy, including those in long term follow-up, between 1 to 53 months after starting treatment with rucaparib (n = 1,146); 8 of these patients developed MDS/AML during treatment or during the 28-day safety follow-up. All patients had received prior treatment with platinum-containing chemotherapy and other DNA damaging agents. MDS and/or AML was not observed in patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination deficiency (HRD) mutation. Monitor complete blood counts (CBC) prior to starting therapy and monthly thereafter. Rucaparib should not be started until any prior hematologic toxicity resolves to grade 1 or less. For prolonged hematologic toxicity (greater than 4 weeks), hold therapy or reduce the dose and check a CBC every week until recovery. If resolution to grade 1 or less has not occurred after 4 weeks or if MDS/AML is suspected, the patient should be referred to a hematologist for further investigations including a bone marrow analysis and cytogenetics. Rucaparib should be discontinued if a diagnosis of MDS or AML is confirmed.[61608]

        Pregnancy should be avoided by females of reproductive potential during rucaparib treatment and for at least 6 months after the last dose. Although there are no adequately controlled studies in humans, rucaparib can cause fetal harm or death when administered during pregnancy based on its mechanism of action and animal studies. Administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death in all animals at exposures equal to 0.04 times the AUC expected at recommended human doses.[61608]

        Counsel patients about the reproductive risk and contraception requirements during rucaparib treatment. Rucaparib can be cause embryo-fetal death if taken by the mother during pregnancy. Females should avoid pregnancy and use effective contraception during and for at least 6 months after treatment. Females of reproductive potential should undergo pregnancy testing prior to initiation of rucaparib. Due to the risk of male-mediated teratogenicity, males with female partners of reproductive potential should not donate sperm and should use effective contraception during treatment and for 3 months after the last dose. Women who become pregnant while receiving rucaparib should be apprised of the potential hazard to the fetus. Fertility studies have not been conducted; however, there were no effects on male or female reproductive organs in rats or dogs at exposures of 0.09 to 0.3 times the exposures expected with recommended dosing in humans.[61608]

        Due to the potential for serious adverse reactions in nursing infants from rucaparib, advise women to discontinue breast-feeding during treatment and for 2 weeks after the final dose. It is not known whether rucaparib is present in human milk, although many drugs are excreted in human milk.[61608]

        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

        Mechanism of Action

        Rucaparib inhibits poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. In vitro, inhibition of PARP enzyme activity by rucaparib results in increased PARP-DNA complexes, causing DNA damage, apoptosis, and cell death. Increased cytotoxicity has been observed with rucaparib exposure in tumor cell lines with deficiencies in BRCA 1/2 and other DNA repair genes. In mouse xenograft models of human cancer with or without BRCA deficiencies, rucaparib has been shown to decrease tumor growth.[61608]

        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

        Pharmacokinetics

        Rucaparib is administered orally. In vitro, rucaparib is 70% protein bound in human plasma. It is preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.8. The mean apparent volume of distribution is 2,300 liters (CV, 21%). The mean terminal half-life of rucaparib is 26 hours (CV, 39%). The mean apparent clearance at steady-state is 44.2 L/hour (CV, 45%). After administration of a single radiolabeled dose, unchanged rucaparib accounted for 64% of the radioactivity in plasma. Rucaparib accounted for 45% of radioactivity in the urine and 95% of radioactivity in the feces.[61608]

         

        Affected cytochrome P450 isoenzymes (CYP450) or drug transporters: CYP1A2, CYP2C9, CYP2C19, CYP3A4

        In vitro, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Additionally, N-demethylation, N-methylation, and glucuronidation are involved in rucaparib metabolism. In vitro, rucaparib is a substrate of P-glycoprotein (P-gp) and BCRP. In clinical studies, rucaparib is a moderate CYP1A2 inhibitor as well as a weak inhibitor of CYP2C9, CYP2C19, CYP3A4, and P-gp. In vitro, rucaparib inhibited CYP2C8, CYP2D6, UGT1A1, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2K, OCT1, OCT2, and MRP4; it induced CYP1A2.[61608]

        Route-Specific Pharmacokinetics

        Oral Route

        The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of rucaparib has not been fully characterized. The mean steady-state Cmax of rucaparib at the approved recommended dosing was 1,940 ng/mL (CV, 54%), reached at a Tmax of 1.9 hours (range, 0 to 5.98 hours). The AUC was 16,900 ng x hour/mL (CV, 54%), and the mean AUC accumulation ratio was 3.5-fold to 6.2-fold. Mean absolute bioavailability is 36% (range, 30% to 45%). The pharmacokinetics (AUC and Cmax) of rucaparib were linear from a dose of 240 mg to 840 mg twice daily.[61608]

        A high-fat meal (approximately 800 to 1,000 calories; 250 calories from carbohydrates, 500 to 600 calories from fat, and 150 calories from protein) increased the Cmax by 20% and the AUC by 38%, while the Tmax was delayed by 2.5 hours as compared to fasting conditions.[61608]

        Special Populations

        Hepatic Impairment

        Mild hepatic impairment (total bilirubin less than the upper limit of normal [ULN] and AST greater than ULN; or total bilirubin 1.1 to 1.5 times ULN and any AST) did not have a clinically meaningful effect on the pharmacokinetics of rucaparib. Moderate hepatic impairment (total bilirubin 1.6 to 3 times ULN and any AST) increased the AUC of rucaparib by 45% but had no effect on Cmax compared to patients with normal hepatic function. The effect of severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) has not been studied.[61608]

        Renal Impairment

        Mild to moderate renal impairment (CrCl 30 mL/min or higher) did not have a clinically meaningful effect on the pharmacokinetics of rucaparib. The effect of severe renal impairment (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min) has not been studied.[61608]

        Pediatrics

        The safety and efficacy of rucaparib has not been established in pediatric patients.[61608]

        Geriatric

        Age (20 to 86 years) does not have a clinically meaningful effect on the pharmacokinetics of rucaparib.[61608]

        Gender Differences

        Sex does not have a clinically meaningful effect on the pharmacokinetics of rucaparib.[61608]

        Ethnic Differences

        Race (White, Black, and Asian) does not have a clinically meaningful effect on the pharmacokinetics of rucaparib.[61608]

        Obesity

        Body weight (41 to 171 kg) does not have a clinically meaningful effect on the pharmacokinetics of rucaparib.[61608]

        Other

        Pharmacogenomics

        CYP2D6 or CYP1A2 genotype polymorphisms did not have a clinically meaningful effect on the pharmacokinetics of rucaparib.[61608]

        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

        Pregnancy/Breast-feeding

        pregnancy

        Pregnancy should be avoided by females of reproductive potential during rucaparib treatment and for at least 6 months after the last dose. Although there are no adequately controlled studies in humans, rucaparib can cause fetal harm or death when administered during pregnancy based on its mechanism of action and animal studies. Administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death in all animals at exposures equal to 0.04 times the AUC expected at recommended human doses.[61608]

        breast-feeding

        Due to the potential for serious adverse reactions in nursing infants from rucaparib, advise women to discontinue breast-feeding during treatment and for 2 weeks after the final dose. It is not known whether rucaparib is present in human milk, although many drugs are excreted in human milk.[61608]

        Revision Date: 03/28/2024, 01:48:00 AM

        References

        61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.

        Interactions

        Level 1 (Severe)

        • Fezolinetant

        Level 2 (Major)

        • Alosetron
        • Alprazolam
        • Bendamustine
        • Eliglustat
        • Erlotinib
        • Lemborexant
        • Lomitapide
        • Lonafarnib
        • Mavacamten
        • Nanoparticle Albumin-Bound Sirolimus
        • Nisoldipine
        • Pimozide
        • Pirfenidone
        • Porfimer
        • Propafenone
        • Rasagiline
        • Tizanidine
        • Ubrogepant

        Level 3 (Moderate)

        • Acetaminophen; Aspirin, ASA; Caffeine
        • Acetaminophen; Caffeine
        • Acetaminophen; Caffeine; Dihydrocodeine
        • Acetaminophen; Caffeine; Pyrilamine
        • Acetaminophen; Codeine
        • Acetaminophen; Hydrocodone
        • Acetaminophen; Oxycodone
        • Alfentanil
        • Amitriptyline
        • Amlodipine; Celecoxib
        • Aripiprazole
        • Aspirin, ASA; Butalbital; Caffeine
        • Aspirin, ASA; Caffeine
        • Aspirin, ASA; Caffeine; Orphenadrine
        • Aspirin, ASA; Carisoprodol; Codeine
        • Aspirin, ASA; Oxycodone
        • Belzutifan
        • Bupivacaine; Lidocaine
        • Bupivacaine; Meloxicam
        • Buprenorphine
        • Buprenorphine; Naloxone
        • Butalbital; Acetaminophen; Caffeine
        • Butalbital; Acetaminophen; Caffeine; Codeine
        • Butalbital; Aspirin; Caffeine; Codeine
        • Caffeine
        • Caffeine; Sodium Benzoate
        • Carbamazepine
        • Celecoxib
        • Celecoxib; Tramadol
        • Chlordiazepoxide; Amitriptyline
        • Chlorpheniramine; Codeine
        • Chlorpheniramine; Hydrocodone
        • Cholera Vaccine
        • Cisapride
        • Citalopram
        • Clomipramine
        • Clopidogrel
        • Clozapine
        • Codeine
        • Codeine; Guaifenesin
        • Codeine; Guaifenesin; Pseudoephedrine
        • Codeine; Phenylephrine; Promethazine
        • Codeine; Promethazine
        • Cyclosporine
        • Dengue Tetravalent Vaccine, Live
        • Diazepam
        • Diclofenac
        • Diclofenac; Misoprostol
        • Disopyramide
        • Dofetilide
        • Ergotamine; Caffeine
        • Felodipine
        • Fentanyl
        • Finerenone
        • Flibanserin
        • Fluoxetine
        • Fluvastatin
        • Fosphenytoin
        • Homatropine; Hydrocodone
        • Hydrocodone
        • Hydrocodone; Ibuprofen
        • Ibuprofen; Oxycodone
        • Ixabepilone
        • Lidocaine
        • Lidocaine; Epinephrine
        • Lidocaine; Prilocaine
        • Mefloquine
        • Meloxicam
        • Methadone
        • Midazolam
        • Nateglinide
        • Nimodipine
        • Olanzapine; Fluoxetine
        • Ospemifene
        • Oxycodone
        • Perphenazine; Amitriptyline
        • Phenobarbital
        • Phenobarbital; Hyoscyamine; Atropine; Scopolamine
        • Phenytoin
        • Primidone
        • Propranolol
        • Ramelteon
        • Riluzole
        • Roflumilast
        • SARS-CoV-2 (COVID-19) vaccines
        • SARS-CoV-2 Virus (COVID-19) Adenovirus Vector Vaccine
        • SARS-CoV-2 Virus (COVID-19) mRNA Vaccine
        • SARS-CoV-2 Virus (COVID-19) Recombinant Spike Protein Nanoparticle Vaccine
        • Sirolimus
        • Sufentanil
        • Tacrolimus
        • Theophylline, Aminophylline
        • Tramadol
        • Tramadol; Acetaminophen
        • Triazolam
        • Verteporfin
        • Vinorelbine
        • Voriconazole
        • Warfarin

        Level 4 (Minor)

        • Isradipine
        Acetaminophen; Aspirin, ASA; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Acetaminophen; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Acetaminophen; Caffeine; Dihydrocodeine: (Moderate) Concomitant use of dihydrocodeine with rucaparib may increase dihydrocodeine plasma concentrations, resulting in greater metabolism by CYP2D6, increased dihydromorphine concentrations, and prolonged opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. If coadministration is necessary, monitor patients closely at frequent intervals and consider a dosage reduction of dihydrocodeine until stable drug effects are achieved. Discontinuation of rucaparib could decrease dihydrocodeine plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to dihydrocodeine. If rucaparib is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Rucaparib is a weak inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of dihydrocodeine. [30282] [61608] (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Acetaminophen; Caffeine; Pyrilamine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Acetaminophen; Codeine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Acetaminophen; Hydrocodone: (Moderate) Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like rucaparib can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. These effects could be more pronounced in patients also receiving a CYP2D6 inhibitor. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. [30379] [56303] [58531] [61608] Acetaminophen; Oxycodone: (Moderate) Consider a reduced dose of oxycodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the oxycodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Oxycodone is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase oxycodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of oxycodone. If rucaparib is discontinued, oxycodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to oxycodone. [39926] [61608] Alfentanil: (Moderate) Consider a reduced dose of alfentanil with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the alfentanil dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Alfentanil is a sensitive CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase alfentanil exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of alfentanil. If rucaparib is discontinued, alfentanil plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to alfentanil. [30072] [61608] Alosetron: (Major) Avoid coadministration of alosetron and rucaparib unless clinically necessary due to the risk of increased plasma concentrations of alosetron. Alosetron is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration with a strong CYP1A2 inhibitor increased alosetron exposure by approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant use with moderate CYP1A2 inhibitors has not been evaluated, but is expected to have similar potential drug interactions. [28382] [61608] Alprazolam: (Major) Avoid coadministration of alprazolam and rucaparib due to the potential for elevated alprazolam concentrations, which may cause prolonged sedation and respiratory depression. If coadministration is necessary, consider reducing the dose of alprazolam as clinically appropriate and monitor for an increase in alprazolam-related adverse reactions. Lorazepam, oxazepam, or temazepam may be safer alternatives if a benzodiazepine must be administered in combination with rucaparib, as these benzodiazepines are not oxidatively metabolized. Alprazolam is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration with another weak CYP3A4 inhibitor increased alprazolam maximum concentration by 82%, decreased clearance by 42%, and increased half-life by 16%. [28040] [61608] Amitriptyline: (Moderate) Monitor for an increase in amitriptyline-related adverse reactions if coadministration with rucaparib is necessary; a dose reduction of amitriptyline may be necessary. Concurrent use may increase the plasma concentrations of amitriptyline. Amitriptyline is a CYP2D6 substrate and rucaparib is a CYP2D6 inhibitor. [28557] [61608] Amlodipine; Celecoxib: (Moderate) Monitor for an increase in celecoxib-related adverse reactions if coadministration with rucaparib is necessary. Celecoxib is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [28317] [61608] Aripiprazole: (Moderate) Monitor for aripiprazole-related adverse reactions during concomitant use of rucaparib. Patients receiving both a CYP2D6 inhibitor plus rucaparib may require an aripiprazole dosage adjustment. Dosing recommendations vary based on aripiprazole dosage form, CYP2D6 inhibitor strength, and CYP2D6 metabolizer status. See prescribing information for details. Concomitant use may increase aripiprazole exposure and risk for side effects. Aripiprazole is a CYP3A and CYP2D6 substrate; rucaparib is a weak CYP3A inhibitor. [42845] [53394] [60196] [61608] [63328] [68911] Aspirin, ASA; Butalbital; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Aspirin, ASA; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Aspirin, ASA; Caffeine; Orphenadrine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Aspirin, ASA; Carisoprodol; Codeine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Aspirin, ASA; Oxycodone: (Moderate) Consider a reduced dose of oxycodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the oxycodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Oxycodone is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase oxycodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of oxycodone. If rucaparib is discontinued, oxycodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to oxycodone. [39926] [61608] Belzutifan: (Moderate) Monitor for anemia and hypoxia if concomitant use of rucaparib with belzutifan is necessary due to increased plasma exposure of belzutifan which may increase the incidence and severity of adverse reactions. Reduce the dose of belzutifan as recommended if anemia or hypoxia occur. Belzutifan is a CYP2C19 substrate and rucaparib is a CYP2C19 inhibitor. [61608] [66875] Bendamustine: (Major) Consider the use of an alternative therapy if rucaparib treatment is needed in patients receiving bendamustine. Rucaparib may increase bendamustine exposure, which may increase the risk of adverse reactions (e.g., myelosuppression, infection, hepatotoxicity). Bendamustine is a CYP1A2 substrate and rucaparib is a CYP1A2 inhibitor. [55945] [60454] [61608] [64723] Bupivacaine; Lidocaine: (Moderate) Monitor for an increase in lidocaine-related adverse reactions if coadministration with rucaparib is necessary. Lidocaine is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration may increase lidocaine plasma concentrations. [31536] [31537] [31538] [31539] [61608] Bupivacaine; Meloxicam: (Moderate) Consider a meloxicam dose reduction and monitor for adverse reactions if coadministration with rucaparib is necessary. Concurrent use may increase meloxicam exposure. Meloxicam is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [61608] [65019] Buprenorphine: (Moderate) Concomitant use of buprenorphine and rucaparib can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when rucaparib is added after a stable buprenorphine dose is achieved. If concurrent use is necessary, consider dosage reduction of buprenorphine until stable drug effects are achieved. Monitor patient for respiratory depression and sedation at frequent intervals. When stopping rucaparib, the buprenorphine concentration may decrease, potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependency. If rucaparib is discontinued, consider increasing buprenorphine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. Buprenorphine is a substrate of CYP3A4 and rucaparib is a CYP3A4 inhibitor. [41235] [41666] [61608] Buprenorphine; Naloxone: (Moderate) Concomitant use of buprenorphine and rucaparib can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when rucaparib is added after a stable buprenorphine dose is achieved. If concurrent use is necessary, consider dosage reduction of buprenorphine until stable drug effects are achieved. Monitor patient for respiratory depression and sedation at frequent intervals. When stopping rucaparib, the buprenorphine concentration may decrease, potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependency. If rucaparib is discontinued, consider increasing buprenorphine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. Buprenorphine is a substrate of CYP3A4 and rucaparib is a CYP3A4 inhibitor. [41235] [41666] [61608] Butalbital; Acetaminophen; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Butalbital; Acetaminophen; Caffeine; Codeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Butalbital; Aspirin; Caffeine; Codeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.55-fold. [27950] [61608] (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Caffeine; Sodium Benzoate: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Carbamazepine: (Moderate) Monitor carbamazepine concentrations closely during coadministration of rucaparib; carbamazepine dose adjustments may be needed. Concomitant use may increase carbamazepine concentrations. Carbamazepine is a CYP3A4 substrate and rucaparib is a CYP3A4 inhibitor. [41237] [61608] Celecoxib: (Moderate) Monitor for an increase in celecoxib-related adverse reactions if coadministration with rucaparib is necessary. Celecoxib is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [28317] [61608] Celecoxib; Tramadol: (Moderate) Monitor for an increase in celecoxib-related adverse reactions if coadministration with rucaparib is necessary. Celecoxib is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [28317] [61608] (Moderate) Monitor for an increase in tramadol-related adverse reactions, including serotonin syndrome, seizures, sedation, and respiratory depression, if coadministration with rucaparib is necessary; the risk is greatest if rucaparib is added to a stable dose of tramadol. Consider decreasing the dose of tramadol if necessary. Rucaparib is a weak CYP3A4 inhibitor and tramadol is metabolized by both CYP3A4 and CYP2D6. Coadministration with a CYP3A4 inhibitor may result in a greater amount of tramadol metabolism via CYP2D6, and greater levels of the active metabolite, M1. [28314] [32475] [61608] Chlordiazepoxide; Amitriptyline: (Moderate) Monitor for an increase in amitriptyline-related adverse reactions if coadministration with rucaparib is necessary; a dose reduction of amitriptyline may be necessary. Concurrent use may increase the plasma concentrations of amitriptyline. Amitriptyline is a CYP2D6 substrate and rucaparib is a CYP2D6 inhibitor. [28557] [61608] Chlorpheniramine; Codeine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Chlorpheniramine; Hydrocodone: (Moderate) Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like rucaparib can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. These effects could be more pronounced in patients also receiving a CYP2D6 inhibitor. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. [30379] [56303] [58531] [61608] Cholera Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the live cholera vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to cholera bacteria after receiving the vaccine. [60871] Cisapride: (Moderate) Monitor for an increase in cisapride-related adverse reactions if concurrent treatment with rucaparib is necessary, as plasma concentrations of cisapride may increase. Cisapride is a CYP3A4 substrate with a narrow therapeutic index and rucaparib is a weak CYP3A inhibitor. [47221] [61608] Citalopram: (Moderate) The maximum daily dose of citalopram in patients receiving concomitant treatment with rucaparib is 20 mg. Monitor for an increase in citalopram-related adverse reactions, including QT prolongation. Citalopram is a CYP2C19 substrate and rucaparib is a weak CYP2C19 inhibitor. [28269] [61608] Clomipramine: (Moderate) Monitor for an increase in clomipramine-related adverse reactions if concurrent use of rucaparib is necessary as plasma concentrations of clomipramine may increase; a dose reduction of clomipramine may be necessary. Clomipramine is a CYP2D6 and CYP1A2 substrate; rucaparib is a weak CYP2D6 inhibitor and a moderate CYP1A2 inhibitor. [57093] [61608] Clopidogrel: (Moderate) Monitor for decreased efficacy of clopidogrel if coadministration with rucaparib is necessary. Clopidogrel is a prodrug that is metabolized to its active metabolite by CYP2C19. Rucaparib is a weak CYP2C19 inhibitor. Concomitant use may reduce concentrations of the active metabolite, therefore decreasing the antiplatelet activity of clopidogrel. [28435] [61608] Clozapine: (Moderate) Monitor for an increase in clozapine-related adverse reactions (e.g., sedation, orthostasis, seizures, and QT prolongation) if coadministration with rucaparib is necessary; consider reducing the dose of clozapine if needed. If rucaparib is discontinued, monitor for a lack of efficacy, increasing the clozapine dose if necessary. Clozapine is a CYP1A2 and CYP3A4 substrate. Rucaparib is a moderate CYP1A2 inhibitor as well as a weak CYP3A4 inhibitor. Coadministration may increase plasma concentrations of clozapine. [28262] [61608] Codeine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Codeine; Guaifenesin: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Codeine; Guaifenesin; Pseudoephedrine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Codeine; Phenylephrine; Promethazine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Codeine; Promethazine: (Moderate) Monitor for an increase in codeine-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary; consider reducing the dose of codeine if clinically appropriate. If rucaparib is discontinued, monitor for evidence of opioid withdrawal until stable drug effects are achieved and consider increasing the codeine dose if necessary. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norcodeine; norcodeine does not have analgesic properties. Rucaparib is a weak CYP3A4 inhibitor. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations. [30634] [33654] [61608] Cyclosporine: (Moderate) Monitor cyclosporine levels and watch for cyclosporine-related adverse reactions if coadministration with rucaparib is necessary. Cyclosporine is a CYP3A4 substrate with a narrow therapeutic index and rucaparib is a weak CYP3A4 inhibitor. Concomitant use may increase plasma concentrations of cyclosporine. [28404] [61608] Dengue Tetravalent Vaccine, Live: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the dengue virus vaccine. When feasible, administer indicated vaccines at least 2 weeks prior to initiating immunosuppressant medications. If vaccine administration is necessary, consider revaccination following restoration of immune competence. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure after receiving the vaccine. [60092] [64100] [65107] Diazepam: (Moderate) Monitor for an increase in diazepam-related adverse reactions including sedation and respiratory depression if coadministration with rucaparib is necessary. Diazepam is a CYP2C19 substrate and rucaparib is a weak CYP2C19 inhibitor. Concomitant use may increase plasma concentrations of diazepam. [28556] [55901] [61608] Diclofenac: (Moderate) Monitor for an increase in diclofenac-related adverse reactions if coadministration with rucaparib is necessary. Diclofenac is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [40916] [61608] Diclofenac; Misoprostol: (Moderate) Monitor for an increase in diclofenac-related adverse reactions if coadministration with rucaparib is necessary. Diclofenac is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [40916] [61608] Disopyramide: (Moderate) Monitor for an increase in disopyramide-related adverse reactions if coadministration with rucaparib is necessary. Disopyramide is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor; concomitant use may increase plasma concentrations of disopyramide. Specific drug interaction studies have not been done for disopyramide; however, cases of life-threatening interactions have been reported when coadministered with moderate and strong CYP3A4 inhibitors. Coadministration of disopyramide with CYP3A4 inhibitors could result in a potentially fatal interaction. [28228] [61608] Dofetilide: (Moderate) Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with rucaparib is necessary. Rucaparib is a weak CYP3A4 inhibitor and dofetilide is a minor CYP3A4 substrate; however, because there is a linear relationship between dofetilide plasma concentration and QTc, concomitant administration of CYP3A4 inhibitors may increase the risk of arrhythmia (torsade de pointes). [28221] [61608] Eliglustat: (Major) In poor CYP2D6 metabolizers (PMs), coadministration of rucaparib and eliglustat is not recommended. Rucaparib is a weak CYP3A inhibitor; eliglustat is a CYP3A substrate. In extensive CYP2D6 metabolizers (EM) with mild hepatic impairment, coadministration of these agents requires dosage reduction of eliglustat to 84 mg PO once daily. Because CYP3A plays a significant role in the metabolism of eliglustat in CYP2D6 PMs, coadministration of eliglustat with CYP3A inhibitors may increase eliglustat exposure and the risk of serious adverse events (e.g., QT prolongation and cardiac arrhythmias) in these patients. [57803] [61608] Ergotamine; Caffeine: (Moderate) Monitor for an increase in caffeine-related adverse reactions if coadministration with rucaparib is necessary. Some patients may need to reduce or limit their caffeine intake. Caffeine is a sensitive CYP1A2 substrate and rucaparib is a weak CYP1A2 inhibitor. Concomitant use increased the AUC of caffeine by 2.6-fold. [27950] [61608] Erlotinib: (Major) Avoid coadministration of erlotinib with rucaparib if possible due to the increased risk of erlotinib-related adverse reactions. If concomitant use is unavoidable and severe reactions occur, reduce the dose of erlotinib by 50 mg decrements. Erlotinib is primarily metabolized by CYP3A and to a lesser extent by CYP1A2; rucaparib is a CYP3A and CYP1A2 inhibitor. Coadministration with a moderate CYP3A/CYP1A2 inhibitor increased erlotinib exposure by 39% and increased the erlotinib Cmax by 17%. [30555] [61608] Felodipine: (Moderate) Monitor blood pressure if coadministration of felodipine and rucaparib is necessary. Felodipine is a sensitive substrate of CYP3A4 and rucaparib is a weak CYP3A4 inhibitor. Concomitant use may increase felodipine exposure. [28541] [61608] Fentanyl: (Moderate) Consider a reduced dose of fentanyl with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the fentanyl dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Fentanyl is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase fentanyl exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of fentanyl. If rucaparib is discontinued, fentanyl plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to fentanyl. [29623] [61608] Fezolinetant: (Contraindicated) Concomitant use of fezolinetant and rucaparib is contraindicated due to the risk of increased fezolinetant exposure which may increase the risk of fezolinetant-related adverse effects. Fezolinetant is a CYP1A2 substrate; rucaparib is a moderate CYP1A2 inhibitor. Concomitant use with another moderate CYP1A2 inhibitor increased fezolinetant overall exposure by 360%. [61608] [68990] Finerenone: (Moderate) Monitor serum potassium during initiation or dose adjustment of either finerenone or rucaparib; a finerenone dosage reduction may be necessary. Concomitant use may increase finerenone exposure and the risk of hyperkalemia. Finerenone is a CYP3A substrate and rucaparib is a weak CYP3A inhibitor. Coadministration with another weak CYP3A inhibitor increased overall exposure to finerenone by 21%. [61608] [66793] Flibanserin: (Moderate) Monitor for hypotension, syncope, somnolence, or other flibanserin-related adverse reactions if coadministration with multiple weak CYP3A4 inhibitors, including rucaparib, is necessary. Flibanserin is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Concomitant use of flibanserin and multiple weak CYP3A4 inhibitors may increase flibanserin plasma concentrations. [60099] [61608] Fluoxetine: (Moderate) Monitor for increased fluoxetine-related adverse effects if coadministered with rucaparib. Concurrent use may result in increased fluoxetine exposure. Fluoxetine is a CYP2D6 substrate and rucaparib is a weak CYP2D6 inhibitor. [44058] [61608] Fluvastatin: (Moderate) Monitor for an increase in fluvastatin-related adverse reactions, including myopathy and rhabdomyolysis, if coadministration with rucaparib is necessary. Fluvastatin is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [34498] [45527] [61608] Fosphenytoin: (Moderate) Monitor for an increase in fosphenytoin-related adverse reactions if coadministration with rucaparib is necessary. Fosphenytoin is a CYP2C9 and CYP2C19 substrate. Rucaparib is a weak inhibitor of both of these isoenzymes. Concomitant use may increase plasma concentrations of fosphenytoin. [22005] [55436] [56579] [57046] [61608] Homatropine; Hydrocodone: (Moderate) Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like rucaparib can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. These effects could be more pronounced in patients also receiving a CYP2D6 inhibitor. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. [30379] [56303] [58531] [61608] Hydrocodone: (Moderate) Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like rucaparib can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. These effects could be more pronounced in patients also receiving a CYP2D6 inhibitor. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. [30379] [56303] [58531] [61608] Hydrocodone; Ibuprofen: (Moderate) Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Hydrocodone is a CYP3A4 substrate, and coadministration with CYP3A4 inhibitors like rucaparib can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. These effects could be more pronounced in patients also receiving a CYP2D6 inhibitor. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. [30379] [56303] [58531] [61608] Ibuprofen; Oxycodone: (Moderate) Consider a reduced dose of oxycodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the oxycodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Oxycodone is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase oxycodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of oxycodone. If rucaparib is discontinued, oxycodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to oxycodone. [39926] [61608] Isradipine: (Minor) Monitor blood pressure if coadministration of isradipine with rucaparib is necessary. Isradipine is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. [50771] [61608] [62065] Ixabepilone: (Moderate) Monitor for ixabepilone toxicity and reduce the ixabepilone dose as needed if concurrent use of rucaparib is necessary. Concomitant use may increase ixabepilone exposure and the risk of adverse reactions. Ixabepilone is a CYP3A substrate and rucaparib is a weak CYP3A inhibitor. [33563] [61608] Lemborexant: (Major) Limit the dose of lemborexant to a maximum of 5 mg PO once daily if coadministered with rucaparib as concurrent use may increase lemborexant exposure and the risk of adverse effects. Lemborexant is a CYP3A4 substrate; rucaparib is a weak CYP3A4 inhibitor. Coadministration of lemborexant with a weak CYP3A4 inhibitor is predicted to increase lemborexant exposure by less than 2-fold. [61608] [64870] Lidocaine: (Moderate) Monitor for an increase in lidocaine-related adverse reactions if coadministration with rucaparib is necessary. Lidocaine is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration may increase lidocaine plasma concentrations. [31536] [31537] [31538] [31539] [61608] Lidocaine; Epinephrine: (Moderate) Monitor for an increase in lidocaine-related adverse reactions if coadministration with rucaparib is necessary. Lidocaine is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration may increase lidocaine plasma concentrations. [31536] [31537] [31538] [31539] [61608] Lidocaine; Prilocaine: (Moderate) Monitor for an increase in lidocaine-related adverse reactions if coadministration with rucaparib is necessary. Lidocaine is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration may increase lidocaine plasma concentrations. [31536] [31537] [31538] [31539] [61608] Lomitapide: (Major) The lomitapide dose should not exceed 30 mg per day PO during concurrent use with rucaparib. Lomitapide is a sensitive substrate of CYP3A4 and rucaparib is a weak CYP3A4 inhibitor. The exposure to lomitapide is increased by approximately 2-fold in the presence of weak CYP3A4 inhibitors. [52698] [61608] Lonafarnib: (Major) Avoid coadministration of lonafarnib and rucaparib; concurrent use may increase the exposure of lonafarnib and the risk of adverse effects. If coadministration is unavoidable, reduce to or continue lonafarnib at a dosage of 115 mg/m2 and closely monitor patients for lonafarnib-related adverse reactions. Resume previous lonafarnib dosage 14 days after discontinuing rucaparib. Lonafarnib is a sensitive CYP3A4 and CYP2C9 substrate; rucaparib is a weak CYP3A4 and CYP2C9 inhibitor. [61608] [66129] Mavacamten: (Major) Reduce the mavacamten dose by 1 level (i.e., 15 to 10 mg, 10 to 5 mg, or 5 to 2.5 mg) in patients receiving mavacamten and starting rucaparib therapy. Avoid initiation of rucaparib in patients who are on stable treatment with mavacamten 2.5 mg per day because a lower dose of mavacamten is not available. Initiate mavacamten at the recommended starting dose of 5 mg PO once daily in patients who are on stable rucaparib therapy. Concomitant use increases mavacamten exposure, which may increase the risk of adverse drug reactions. Mavacamten is a CYP2C19 substrate and rucaparib is a weak CYP2C19 inhibitor. Concomitant use with another weak CYP2C19 inhibitor in CYP2C19 normal and rapid metabolizers increased overall mavacamten exposure by 48%. [61608] [67543] Mefloquine: (Moderate) Use mefloquine with caution if coadministration with rucaparib is necessary as concurrent use may increase mefloquine exposure and mefloquine-related adverse events. Mefloquine is a substrate of CYP3A4 and rucaparib is a weak CYP3A4 inhibitor. [28301] [61608] Meloxicam: (Moderate) Consider a meloxicam dose reduction and monitor for adverse reactions if coadministration with rucaparib is necessary. Concurrent use may increase meloxicam exposure. Meloxicam is a CYP2C9 substrate and rucaparib is a weak CYP2C9 inhibitor. [61608] [65019] Methadone: (Moderate) Consider a reduced dose of methadone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the methadone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Methadone is a CYP3A4, CYP2C9, and CYP2C19 substrate; rucaparib is a weak inhibitor of CYP3A4, CYP2C9, and CYP2C19. Coadministration can increase methadone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of methadone. If rucaparib is discontinued, methadone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to methadone. [31280] [32532] [61608] Midazolam: (Moderate) Monitor for an increase in midazolam-related adverse reactions, including sedation and respiratory depression, if coadministration with rucaparib is necessary. Midazolam is a sensitive CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Concomitant use increased the AUC of midazolam by 1.4-fold. [61608] [64166] Nanoparticle Albumin-Bound Sirolimus: (Major) Reduce the nab-sirolimus dose to 56 mg/m2 during concomitant use of rucaparib. Coadministration may increase sirolimus concentrations and increase the risk for sirolimus-related adverse effects. Sirolimus is a CYP3A substrate and rucaparib is a weak CYP3A inhibitor. [61608] [67136] Nateglinide: (Moderate) Monitor for an increase in nateglinide-related adverse effects, such as hypoglycemia, if concomitant use with rucaparib is necessary; a nateglinide dosage reduction may be required. Concomitant use may increase nateglinide exposure. Nateglinide is a CYP2C9 substrate and rucaparib is a CYP2C9 inhibitor. [45644] [61608] Nimodipine: (Moderate) Monitor blood pressure if coadministration of nimodipine with rucaparib is necessary; a reduction of the nimodipine dose may be necessary. Nimodipine is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration with another weak CYP3A4 inhibitor increased mean peak nimodipine plasma concentrations by 50% and increased the mean AUC by 90%. [54661] [61608] Nisoldipine: (Major) Avoid coadministration of nisoldipine with rucaparib due to the risk of increased plasma concentrations of nisoldipine. Nisoldipine is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. [34682] [61608] Olanzapine; Fluoxetine: (Moderate) Monitor for increased fluoxetine-related adverse effects if coadministered with rucaparib. Concurrent use may result in increased fluoxetine exposure. Fluoxetine is a CYP2D6 substrate and rucaparib is a weak CYP2D6 inhibitor. [44058] [61608] Ospemifene: (Moderate) Monitor for an increase in ospemifene-related adverse reactions if coadministration with rucaparib is necessary. Ospemifene is a substrate of CYP2C9, CYP2C19, and CYP3A4, while rucaparib is a weak inhibitor of these 3 isoenzymes. Concomitant use may increase ospemifene plasma concentrations. [53344] [61608] Oxycodone: (Moderate) Consider a reduced dose of oxycodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the oxycodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Oxycodone is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. Coadministration can increase oxycodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of oxycodone. If rucaparib is discontinued, oxycodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to oxycodone. [39926] [61608] Perphenazine; Amitriptyline: (Moderate) Monitor for an increase in amitriptyline-related adverse reactions if coadministration with rucaparib is necessary; a dose reduction of amitriptyline may be necessary. Concurrent use may increase the plasma concentrations of amitriptyline. Amitriptyline is a CYP2D6 substrate and rucaparib is a CYP2D6 inhibitor. [28557] [61608] Phenobarbital: (Moderate) Monitor for an increase in phenobarbital-related adverse reactions if coadministration with rucaparib is necessary. Phenobarbital is a CYP2C9 and CYP2C19 substrate. Rucaparib is a weak inhibitor of both of these isoenzymes. Concomitant use may increase plasma concentrations of phenobarbital. [22005] [55436] [57046] [57048] [61608] Phenobarbital; Hyoscyamine; Atropine; Scopolamine: (Moderate) Monitor for an increase in phenobarbital-related adverse reactions if coadministration with rucaparib is necessary. Phenobarbital is a CYP2C9 and CYP2C19 substrate. Rucaparib is a weak inhibitor of both of these isoenzymes. Concomitant use may increase plasma concentrations of phenobarbital. [22005] [55436] [57046] [57048] [61608] Phenytoin: (Moderate) Monitor for an increase in phenytoin-related adverse reactions if coadministration with rucaparib is necessary. Phenytoin is a CYP2C9 and CYP2C19 substrate. Rucaparib is a weak inhibitor of both of these isoenzymes. Concomitant use may increase plasma concentrations of phenytoin. [22005] [55436] [56579] [57046] [61608] Pimozide: (Major) Avoid coadministration of pimozide with rucaparib due to the increased risk of cardiac effects. Pimozide is a CYP3A4 and CYP1A2 substrate. Rucaparib is a weak CYP3A4 inhibitor and a moderate CYP1A2 inhibitor. Ventricular arrhythmias associated with prolonged QT intervals have occurred with concomitant treatment with both strong and moderate CYP3A4 inhibitors; the manufacturer of pimozide advises that less potent CYP3A4 inhibitors should also be avoided. There is a theoretical potential for additional pimozide-related effects via inhibition of CYP1A2. [43463] [56203] [61608] Pirfenidone: (Major) Reduce the dose of pirfenidone to 534 mg three times daily (1,602 mg/day) if coadministration with rucaparib is necessary. Pirfenidone is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Coadministration with another moderate CYP1A2 inhibitor increased pirfenidone exposure by 81%. [58189] [61608] Porfimer: (Major) Avoid coadministration of porfimer with rucaparib due to the risk of increased photosensitivity. All patients treated with porfimer will be photosensitive. Concomitant use of other photosensitizing agents like rucaparib may increase the risk of a photosensitivity reaction. [42968] [61608] Primidone: (Moderate) Monitor for an increase in primidone-related adverse reactions if coadministration with rucaparib is necessary. Primidone is a CYP2C9 and CYP2C19 substrate. Rucaparib is a weak inhibitor of both of these isoenzymes. Concomitant use may increase plasma concentrations of primidone. [22005] [55436] [56579] [57046] [61608] Propafenone: (Major) Avoid concurrent use of propafenone and rucaparib; concurrent use may increase plasma concentrations of propafenone, which may lead to cardiac arrhythmias and exaggerated beta-blocking activity. Propafenone is a CYP3A4, CYP2D6, and CYP1A2 substrate; rucaparib is a weak CYP3A4 inhibitor, a weak CYP2D6 inhibitor, and a moderate CYP1A2 inhibitor. [53238] [61608] Propranolol: (Moderate) Monitor patients for hypotension and bradycardia if coadministration of propranolol with rucaparib is necessary. Propranolol is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. Concomitant use of CYP1A2 inhibitors may increase exposure to propranolol. [45870] [56853] [61608] Ramelteon: (Moderate) Monitor for an increase in ramelteon-related adverse reactions if coadministration with rucaparib is necessary. Ramelteon is a CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. [31359] [61608] Rasagiline: (Major) Do not exceed a rasagiline dose of 0.5 mg once daily when coadministered with rucaparib. Coadministration may result in increased rasagiline concentrations. Rasagiline is primarily metabolized by CYP1A2; rucaparib is a moderate CYP1A2 inhibitor. When rasagiline was administered with a strong CYP1A2 inhibitor, the AUC of rasagiline increased by 83%. [32223] [61608] Riluzole: (Moderate) Coadministration of riluzole with rucaparib may increase the risk for riluzole-related adverse reactions, such as gastrointestinal symptoms and elevated hepatic enzymes. In vitro findings suggest an increase in riluzole exposure is likely; riluzole is a CYP1A2 substrate and rucaparib is a CYP1A2 inhibitor. [29747] [61608] Roflumilast: (Moderate) Monitor for an increase in roflumilast-related adverse reactions if coadministration with rucaparib is necessary. A major step in roflumilast metabolism is the N-oxidation of roflumilast to roflumilast N-oxide by CYP3A4 and CYP1A2. Rucaparib is a moderate CYP1A2 inhibitor and a weak inhibitor of CYP3A4. Dual inhibitors of CYP3A4 and CYP1A2 may increase roflumilast exposure. [43551] [61608] SARS-CoV-2 (COVID-19) vaccines: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) Adenovirus Vector Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) mRNA Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) Recombinant Spike Protein Nanoparticle Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] Sirolimus: (Moderate) Monitor sirolimus concentrations and adjust sirolimus dosage as appropriate during concomitant use of rucaparib. Coadministration may increase sirolimus concentrations and increase the risk for sirolimus-related adverse effects. Sirolimus is a CYP3A substrate and rucaparib is a weak CYP3A inhibitor. [28610] [61608] Sufentanil: (Moderate) Because the dose of the sufentanil sublingual tablets cannot be titrated, consider an alternate opiate if rucaparib must be administered. Consider a reduced dose of sufentanil injection with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the sufentanil injection dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Sufentanil is a CYP3A4 substrate, and coadministration with a weak CYP3A4 inhibitor like rucaparib can increase sufentanil exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of sufentanil. If rucaparib is discontinued, sufentanil plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to sufentanil. [30966] [61608] [63731] Tacrolimus: (Moderate) Frequently monitor tacrolimus levels and watch for an increase in tacrolimus-related adverse reactions if coadministration with rucaparib is necessary. Tacrolimus is a sensitive substrate of CYP3A4 and rucaparib is a weak CYP3A4 inhibitor. [28611] [61608] Theophylline, Aminophylline: (Moderate) Monitor theophylline levels and watch for an increase in theophylline-related adverse reactions if coadministration with rucaparib is necessary; a theophylline dose reduction may be necessary. Theophylline is a CYP1A2 substrate with a narrow therapeutic index and rucaparib is a moderate CYP1A2 inhibitor. [50760] [61608] (Minor) Monitor theophylline levels and watch for an increase in theophylline-related adverse reactions if coadministration with rucaparib is necessary; a theophylline dose reduction may be necessary. Theophylline is a CYP1A2 substrate with a narrow therapeutic index and rucaparib is a moderate CYP1A2 inhibitor. [50760] [61608] Tizanidine: (Major) Avoid coadministration of tizanidine with rucaparib if possible due the risk of increased plasma concentrations of tizanidine. If concomitant use is unavoidable, monitor for an increase in tizanidine-related adverse reactions (e.g., hypotension, bradycardia, excessive drowsiness). Tizanidine is a sensitive CYP1A2 substrate and rucaparib is a moderate CYP1A2 inhibitor. [52430] [61608] Tramadol: (Moderate) Monitor for an increase in tramadol-related adverse reactions, including serotonin syndrome, seizures, sedation, and respiratory depression, if coadministration with rucaparib is necessary; the risk is greatest if rucaparib is added to a stable dose of tramadol. Consider decreasing the dose of tramadol if necessary. Rucaparib is a weak CYP3A4 inhibitor and tramadol is metabolized by both CYP3A4 and CYP2D6. Coadministration with a CYP3A4 inhibitor may result in a greater amount of tramadol metabolism via CYP2D6, and greater levels of the active metabolite, M1. [28314] [32475] [61608] Tramadol; Acetaminophen: (Moderate) Monitor for an increase in tramadol-related adverse reactions, including serotonin syndrome, seizures, sedation, and respiratory depression, if coadministration with rucaparib is necessary; the risk is greatest if rucaparib is added to a stable dose of tramadol. Consider decreasing the dose of tramadol if necessary. Rucaparib is a weak CYP3A4 inhibitor and tramadol is metabolized by both CYP3A4 and CYP2D6. Coadministration with a CYP3A4 inhibitor may result in a greater amount of tramadol metabolism via CYP2D6, and greater levels of the active metabolite, M1. [28314] [32475] [61608] Triazolam: (Moderate) Monitor for signs of triazolam toxicity during coadministration with rucaparib and consider appropriate dose reduction of triazolam if clinically indicated. Coadministration may increase triazolam exposure. Triazolam is a sensitive CYP3A substrate and rucaparib is a weak CYP3A inhibitor. [28556] [41543] [61608] Ubrogepant: (Major) Limit the initial and second dose of ubrogepant to 50 mg if coadministered with rucaparib. Concurrent use may increase ubrogepant exposure and the risk of adverse effects. Ubrogepant is a CYP3A4 substrate; rucaparib is a weak CYP3A4 inhibitor. [61608] [64874] Verteporfin: (Moderate) Use caution if coadministration of verteporfin with rucaparib is necessary due to the risk of increased photosensitivity. Verteporfin is a light-activated drug used in photodynamic therapy; all patients treated with verteporfin will be photosensitive. Concomitant use of other photosensitizing agents like rucaparib may increase the risk of a photosensitivity reaction. [30003] [61608] Vinorelbine: (Moderate) Monitor for an earlier onset and/or increased severity of vinorelbine-related adverse reactions, including constipation and peripheral neuropathy, if coadministration with rucaparib is necessary. Vinorelbine is a CYP3A4 substrate and rucaparib is a weak CYP3A4 inhibitor. [56871] [61608] Voriconazole: (Moderate) Monitor for an increase in voriconazole-related adverse reactions if coadministration with rucaparib is necessary. Voriconazole is a CYP2C19 substrate and rucaparib is a weak CYP2C19 inhibitor. Concomitant use may increase plasma concentrations of voriconazole. [54713] [61608] Warfarin: (Moderate) Closely monitor the INR if coadministration of warfarin with rucaparib is necessary as concurrent use may increase the exposure of warfarin leading to increased bleeding risk. Rucaparib is a weak CYP3A4/CYP2C9/CYP1A2 inhibitor and warfarin is a CYP3A4/CYP2C9/CYP1A2 substrate. [28549] [61608]
        Revision Date: 03/28/2024, 01:48:00 AM

        References

        22005 - Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-255.27950 - Cafcit (caffeine citrate) package insert. Eatontown, NJ: West-Ward Pharmaceuticals; 2019 Dec.28040 - Xanax (alprazolam tablet) package insert. New York, NY: Pharmacia & Upjohn Company; 2023 Jan.28221 - Tikosyn (dofetilide) package insert. New York, NY: Pfizer Labs; 2019 Aug.28228 - Norpace and Norpace CR (disopyramide) package insert. Chicago, IL: G.D. Searle LLC division of Pfizer Inc; 2016 Aug.28262 - Clozaril (clozapine) tablets package insert. Rosemont, PA: HLS Therapeutics (USA), Inc.; 2023 May.28269 - Celexa (citalopram) tablets package insert. North Chicago, IL: AbbVie Inc.; 2023 Oct.28301 - Mefloquine hydrochloride package insert. North Wales PA: Teva Pharmaceuticals USA Inc.; 2019 Mar.28314 - Tramadol hydrochloride tablets package insert. Parsippany, NJ: Teva Pharmaceuticals; 2023 Dec.28317 - Celebrex (celecoxib) package insert. New York, NY: Pfizer, Inc.; 2013 Jan.28382 - Lotronex (alosetron) package insert. San Diego, CA: Promethus Laboratories, Inc.; 2019 April.28404 - Neoral (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Sept.28435 - Plavix (clopidogrel) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2022 Sept28541 - Felodipine package insert. East Windsor, NJ: Aurobindo Pharma USA, Inc.; 2020 Jan.28549 - Coumadin (warfarin tablets) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2017 Aug.28556 - Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther 1999;24:347-55.28557 - Elavil (amitriptyline) tablet package insert. Birmingham, AL: Thompson Medical Solutions; 2016 Apr.28610 - Rapamune (sirolimus) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2022 Aug.28611 - Prograf (tacrolimus) capsules, injection, and granules for oral suspension package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2023 Aug.29623 - Fentanyl transdermal system package insert. Webster Groves, MO: SpecGx LLC; 2024 Jan.29747 - Riluzole tablet package insert. Cranbury, NJ: Sun Pharmaceutical Industries Inc.; 2017 Jan.30003 - Visudyne (verteporfin for injection) package insert. Bridgewater, NJ: Bausch Health US, LLC.; 2021 Jul.30072 - Alfentanil hydrochloride injection package insert. Lake Forest, IL: Akorn, Inc.; 2023 Dec.30282 - Synalgos-DC (aspirin; caffeine; dihydrocodeine) capsules package insert. Atlanta, GA: Mikart, Inc.; 2019 Oct.30379 - Hycodan (hydrocodone bitartrate; homatropine methylbromide) package insert. Malvern, PA: Endo Pharmaceuticals Inc.; 2023 Dec.30555 - Tarceva (erlotinib) package insert. Northbrook, IL: OSI Pharmaceuticals, LLC; 2016 Sept.30634 - Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004;351:2827-31.30966 - Sufentanil citrate injection package insert. Lake Forest, IL: Hospira, Inc.; 2023 Dec31280 - Methadose Oral Concentrate and Methadose Sugar-Free Oral Concentrate (methadone hydrochloride oral concentrate) package insert. Webster Groves, MO: SpecGx LLC; 2023 Dec.31359 - Rozerem (ramelteon) tablet package insert. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2021 Nov.31536 - Olkkola KT, Isohanni MH, Hamunen K, et al. The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth Analg 2005;100:1352-6.31537 - Orlando R, Piccoli P, De Martin S, et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004;75:80-8.31538 - Wang JS, Backman JT, Wen X, et al. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacol Toxicol 1999;85:201-5.31539 - Wang JS, Backman JT, Taavitsainen P, et al. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000;28:959-65.32223 - Azilect (rasagiline mesylate) tablets. Kansas City, MO: Teva Neurosciences, Inc.; 2020 Jun.32475 - Tramadol hydrochloride extended-release tablets package insert. Baltimore, MD: Lupin Pharmaceuticals, Inc.; 2023 Sep.32532 - Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004;57(5):600-610.33563 - Ixempra (ixabepilone) for injection package insert. Princeton, NJ: R-Pharm US LLC; 2023 Jan.33654 - Codeine sulfate tablets package insert. Berkeley Heights, NJ: Hikma Pharmaceuticals USA, Inc.; 2023 Dec.34498 - Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by fluvastatin. Clin Pharmacol Ther 1995;58:412-7.34682 - Heinig R, Adelmann HG, Ahr G. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. Eur J Clin Pharmacol 1999;55:57-60.39926 - OxyContin (oxycodone hydrochloride) extended-release tablets package insert. Stamford, CT: Purdue Pharma L.P.; 2023 Dec.40916 - Diclofenac potassium immediate release tablets package insert. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2017 Aug.41235 - Butrans (buprenorphine transdermal system) package insert. Stamford, CT: Purdue Pharma L.P.; 2023 Dec.41237 - Tegretol (carbamazepine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Sep.41543 - Halcion (triazolam) package insert. New York, NY: Pharmacia and Upjohn Company; 2023 Jan.41666 - Suboxone (buprenorphine; naloxone) sublingual film package insert. North Chesterfield, VA: Indivior Inc; 2023 Dec.42845 - Abilify (aripiprazole) tablets, discmelt orally-disintegrating tablets, oral solution, and intramuscular injection package insert. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2022 Nov.42968 - Photofrin (porfimer sodium) package insert. Bannockburn, IL: Pinnacle Biologics, Inc.; 2020 Jan.43463 - Pimozide tablets package insert. Chestnut Ridge, NY: Par Pharmaceuticals; 2017 March.43551 - Daliresp (roflumilast) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2018 Jan.44058 - Prozac Weekly (fluoxetine hydrochloride delayed-release capsules) package insert. Indianapolis, IN: Lilly USA, LLC; 2017 Mar.45527 - Lescol/Lescol XL (fluvastatin capsules/ fluvastatin sodium extended-release tablets) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017 Aug.45644 - Starlix (nateglinide) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; 2021 Oct.45870 - Propranolol HCl injection package insert. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; 2022 May.47221 - Propulsid (cisapride) package insert. Titusville, NJ; Janssen Pharmaceutica; 2006 Oct. NOTE: As of May 2000; Propulsid has only been available in the United States via an investigational limited access program to ensure proper patient screening and prescribing.50760 - Uniphyl (theophylline, anhydrous) tablets package insert. Stamford, CT: Purdue Pharmaceutical Products LP; 2011 Oct.50771 - DynaCirc CR (isradipine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005 Aug.52430 - Tizanidine (Zanaflex) tablets and capsules package insert. 6300 Switzerland: Covis Pharma Zug; 2020 Dec.52698 - Juxtapid (lomitapide) package insert. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; 2019 Dec.53238 - Rhythmol SR (propafenone) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2013 Feb.53344 - Osphena (ospemifene) tablets package insert. Florham Park, N.J: Shionogi, Inc.; 2019 Jan.53394 - Abilify Maintena (aripiprazole) extended-release intramuscular injection package insert. Rockville, MD:Otsuka America Pharmaceutical, Inc.; 2020 June.54661 - Nymalize (nimodipine) oral solution. Atlanta, GA: Arbor Pharmaceuticals, Inc.; 2020 Apr.54713 - VFEND (voriconazole) injection package insert. New York, NY: Pfizer Inc; 2014 Sept.55436 - Patsalos PN, Berry DJ, Bourgeois BF. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276.55901 - Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118:69-86.55945 - Treanda (bendamustine) injection package insert. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2022 Oct.56203 - Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84.56303 - Hydrocodone bitartrate extended-release capsules package insert. Morristown, NJ: Alvogen, Inc.; 2023 Dec.56579 - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Updated Mar 10, 2020. Retrieved from the World Wide Web at www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm56853 - Hemangeol (propranolol hydrochloride) oral solution package insert. Parsippany, NJ: Pierre Fabre Pharmaceuticals, Inc.; 2021 Jun.56871 - Navelbine (vinorelbine) injection package insert. Parsippany, NJ: Pierre Fabre Pharmaceuticals Inc; 2020 Jan.57046 - Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.57048 - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Retrieved from the World Wide Web December 27, 2013. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#major57093 - Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-64.57803 - Cerdelga (eliglustat) capsules. Waterford, Ireland: Genzyme Ireland, Ltd.;2018 Sept.58189 - Esbriet (pirfenidone) capsules and film-coated tablets package insert. South San Fransisco, CA: Genentech USA, Inc.; 2023 Feb.58531 - Hysingla ER (hydrocodone) extended release tablets package insert. Stamford, CT: Purdue Pharma L.P.; 2023 Dec.60092 - Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58: e44-100.60099 - Addyi (flibanserin tablets) package insert. Raleigh, NC: Sprout Pharmaceuticals, Inc.; 2021 Sept.60196 - Aristada (aripiprazole lauroxil) extended-release intramuscular suspension package insert. Waltham, MA: Alkermes, Inc.; 2020 Feb.60454 - Bendeka (bendamustine hydrochloride) injection package insert. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2024 Jan.60871 - Vaxchora (Cholera Vaccine, live, oral) package insert. Redwood City, CA: Emergent Travel Health Inc.; 2022 Dec.61608 - Rubraca (rucaparib) package insert. Boulder, CO: Clovis Oncology, Inc; 2022 Dec.62065 - Isradipine package insert. Parsippany, NJ: Watson Pharma, Inc.; 2014 June.63328 - Aristada Initio (aripiprazole lauroxil extended-release injectable suspension) package insert. Altham, MA:Alkermes, Inc.; 2020 Feb.63731 - Dsuvia (sufentanil) sublingual tablets package insert. Hayward, CA: AcelRx Pharmaceuticals, Inc.; 2023 Dec.64100 - Dengvaxia (dengue tetravalent vaccine, live) package insert. Swiftwater, PA: Sanofi Pasteur Inc.; 2023 August.64166 - Nayzilam (midazolam) nasal spray package insert. Smyrna, GA: UCG, Inc.; 2023 Jan.64723 - Belrapzo (bendamustine) injection package insert. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2024 Jan.64870 - Dayvigo (lemborexant) tablets package insert. Nutley, NJ: Eisai Inc.; 2023 Apr.64874 - Ubrelvy (ubrogepant) tablets package insert. Madison, NJ: Allergan USA, Inc.; 2023 Feb.65019 - Anjeso (meloxicam) injection package insert. Malvern, PA: Baudax Bio, Inc; 2021 Jul.65107 - Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Accessed April 25, 2024. Available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.66080 - Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers Administering Vaccine: Emergency Use Authorization (EUA) of Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) for 12 years and older. Purple cap and purple border. Retrieved November 22, 2022.66129 - Zokinvy (lonafarnib) capsules package insert. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; 2020 Nov.66793 - Kerendia (finerenone) tablets package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2022 Sept.66875 - Welireg (belzutifan) tablets package insert. Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; 2023 Dec.67136 - Fyarro (sirolimus protein-bound particles) injectable suspension package insert. Pacific Palisades, CA: Aadi Bioscience, Inc.; 2021 Nov.67543 - Camzyos (mavacamten) package insert. Princeton, NJ: Bristol-Myers Squibb; 2024 Apr.68911 - Abilify Asimtufii (aripiprazole) extended-release injectable suspension package insert. Rockville, MD: Otsuka America Pharmaceutical, Inc.; 2023 Apr.68990 - Veozah (fezolinetant) prescribing information. Northbrook, IL: Astellas Pharma US, Inc.; 2023 May

        Monitoring Parameters

        • CBC with differential
        • pregnancy testing

        US Drug Names

        • Rubraca
        Small Elsevier Logo

        Cookies are used by this site. To decline or learn more, visit our cookie notice.


        Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

        Small Elsevier Logo
        RELX Group